Research

From 2012 to 2018, the federal health care program spent $39.7 billion — adjusted for inflation and discounts — on inhalers to help plan beneficiaries combat asthma and chronic obstructive pulmonary disease, or COPD

A new study shows that launch prices of drugs in the United States have more than doubled since a 2005 Medicare policy change.

Real-World Evidence — What Is It and What Can It Tell Us?

No matter how wonderful single-payer health care might be in other respects, it wouldn’t reduce U.S. health-care spending to European levels.

The aim of this study was determine the impact in terms of cost reduction for anticancer drug in the Italian Health Service due to patient participation in clinical trials.

The debate over how best to lower prescription drug prices is expected to continue, but it remains focused on only one component of the problem.

Hospitals Charge Patients More Than Four Times the Cost of Care

A Comparison of the Top 50 Drugs

Trends in Spending and Utilization, 2006-2017

No single manufacturer dominated the top 10 list.

Pricing in a pandemic is complicated and fraught.

When generics enter the market, they are expected to reduce patient costs, but this is not always the case.

Colorado Department of Law, Nov 2020.

Generic drug prices have been capped at specified percentages of the interchangeable branded drug’s price by the Canadian provincial public drug plans since 1993.

Proposals to create a national health care plan such as "Medicare for All" rely heavily on reducing the prices that insurers pay for health care.